Kolon Life Science (102940) is accelerating a shift toward higher-margin businesses, extending the synthesis and quality-control technology it built in antimicrobials and active pharmaceutical ingredients (APIs) into electronic materials and ingredients for next-generation nucleic acid drugs. The strategy calls for raising productivity and opening new markets for existing products to lift profitability, while building gene therapy and contract development and manufacturing (CDMO) operations into future growth pillars.
The product that best illustrates that expansion strategy is pyrithione, according to industry sources on the 1st. It began as an antimicrobial agent used in shampoo. Drawing on pyrithione's ability to suppress microbial growth, the company broadened its applications to preservatives for metalworking fluids, antimicrobial agents for plastics and marine anti-fouling paints. Technology that once curbed dandruff-causing fungi on the scalp evolved into a material that prevents metalworking fluids from spoiling in factories and keeps barnacles from attaching to ships at sea. Helped by the expansion, antimicrobial exports rose nearly 30% in the first half of this year from a year earlier.
The company is also widening its global reach. It jointly developed a core ingredient for next-generation eco-friendly anti-fouling paints with Jotun of Norway, a leading global anti-fouling paint maker, and plans a first shipment to Jotun's China plant within this year. It intends to expand deliveries to Jotun's other global production bases, including Malaysia.
In the API business, a strategy of making older products more competitive is paying off. Loxoprofen, an anti-inflammatory painkiller ingredient and one of its flagship products, has seen manufacturing costs fall 36% and supply volumes rise more than 14-fold through roughly 30 years of process improvements. Kolon Life Science currently supplies 18 APIs to 25 countries and holds 73 drug master file (DMF) registrations. In loxoprofen and nadifloxacin, it has secured supply competitiveness at the world's top level. The technology accumulated in its existing businesses is now reaching into new markets. In functional materials, the company is cultivating polyphenylene oxide (PPO) as a new growth pillar. PPO is a core ingredient for high-performance copper clad laminates (CCL) used in AI accelerators and 5G and 6G network servers. The move extends synthesis technology built in pharmaceuticals and chemicals into the advanced electronic materials market.
In pharmaceuticals, the company is investing in phosphoramidite, an ingredient for RNA therapeutics. Phosphoramidite is a core raw material needed to synthesize nucleic acid drugs such as RNA, and it requires high purity and consistent quality. Kolon Life Science plans to broaden its development and supply range from standard amidites to high-value specialty products.
The bio business is positioned as a medium- to long-term growth driver. KLS-2031, a gene therapy for neuropathic pain, is a candidate that applies three therapeutic genes on a single platform and has completed Phase 1/2a trials in the United States. It received fast-track designation from the U.S. Food and Drug Administration (FDA) in 2020, and the company is pursuing licensing deals and joint development with global partners. KLS-3021, a treatment for solid tumors, uses an oncolytic virus to selectively attack cancer cells while inducing an anti-tumor immune response. It has completed a pre-investigational new drug (Pre-IND) meeting with the FDA, and the company is pursuing global partnering.
The company is expanding manufacturing as well as drug development. Kolon Biotech, a wholly owned subsidiary, handles CDMO work for stem cell, somatic cell and exosome-based therapies at its Chungju plant.
"Rather than resting on the competitiveness of our existing high-value businesses, we are extending the technology we have accumulated into new markets and products," Lee Han-kook, CEO of Kolon Life Science, said. "We will identify new businesses and expand global cooperation to build a foundation for sustained growth."
